Emerging oral drugs for relapsingremitting multiple sclerosis

Expert Opinion on Emerging Drugs

Volumn 16, Issue 4, 2011, Pages 697-712

  Gasperini, Claudio ^a   Ruggieri, Serena ^b  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

BG 12; Cladribine; DMDs; Fingolimod; Laquinimod; Multiple sclerosis; Teriflunomide

Indexed keywords

BETA1A INTERFERON; CLADRIBINE; FINGOLIMOD; FUMARIC ACID; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; LAQUINIMOD; MITOXANTRONE; NATALIZUMAB; PLACEBO; RECOMBINANT INTERFERON; TERIFLUNOMIDE;

ADENOMA; AIRWAY OBSTRUCTION; ALOPECIA; ARTHRALGIA; AUSTRALIA; BONE MARROW SUPPRESSION; BUDD CHIARI SYNDROME; CROHN DISEASE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; FLUSHING; HEADACHE; HUMAN; LIVER TOXICITY; MULTIPLE SCLEROSIS; MYALGIA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL (TOPIC); PLEURISY; PRURITUS; REVIEW; RUSSIAN FEDERATION; SIDE EFFECT;

ADMINISTRATION, ORAL; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME;

EID: 84555191747     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2011.642861     Document Type: Review

References (66)

1. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin 1995;16:119-46
2. Murray TJ. Diagnosis and treatment of multiple sclerosis. BMJ 2006;332:525-7 (Pubitemid 44364370)
3. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17
4. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010;133(Pt 7):1914-12
5. Hu W, Lucchinetti CF. The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol 2009;31:439-53
6. Galetta SL, Markowitz C. US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles. CNS Drugs 2005;19:239-52 (Pubitemid 40460663)
7. Available from: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm226755.htm
8. Australian Therapeutic Goods Administration. Australian public assessment report for cladribine tablets online. Available from: http://www.tga.gov.au/ pdf/auspar/auspar-movectro.pdf Accessed 20 June 2011
9. Carson DA, Wasson DB, Taetle R, et al. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983;62:737-43 (Pubitemid 13008659)
10. Beutler E. New chemotherapeutic agent: 2-chlorodeoxyadenosine. Semin Hematol 1994;31(1):40-5 (Pubitemid 24031130)
11. Schirmer M, Mur E, Pfeiffer KP, et al. The safety profile of low-dose cladribine in refractory rheumatoid arthritis. A pilot trial. Scand J Rheumatol 1997;26:376-9 (Pubitemid 27471223)
12. Beutler E, Sipe JC, Romine JS, et al. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 1996;93:1716-20 (Pubitemid 26075191)
13. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000;54:1145-55 (Pubitemid 30151860)
14. Kopadze T, Dobert M, Leussink VI, et al. Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis. Eur J Neurol 2009;16:409-12
15. Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet 1997;32:120-31 (Pubitemid 27104411)
16. Van Axel Castelli V, Trivieri G, Zucchelli I, et al. Characterisation of an inclusion complex between cladribine and 2-hydroxypropyl-beta-cyclodextrin. J Pharm Sci 2008;97(9):3897-906
17. Muir VJ, Plosker GL. Cladribine tablets: in relapsing-remitting multiple sclerosis. CNS Drugs 2011;25:239-4
18. Giovannoni G, Comi G, Cook S, et al. CLARITY Study Group. A placebo controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362:416-26
19. Stelmasiak Z, Solski J, Nowicki J, et al. Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study. Mult Scler 2009;15:767-70
20. Cook S, Vermersch P, Comi G, et al. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler 2011;17:578-93
21. Rieckmann P, Giovannoni G, Cook SD, et al. Cladribine tablets in relapsing-remitting multiple sclerosis: study design of the 2-year, Phase IIIb CLARITY (CLAdRibine tablets Treating multiple sclerosis orallY) extension study. Mult Scler 2008;14:S161-2
22. Salvadori M, Budde K, Charpentier B, et al. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant 2006;6:2912-21
23. Fujino M, Funeshima N, Kitazawa Y, et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 2003;305:70-7 (Pubitemid 36378136)
24. Chun J, Hartung HP. Mechanism of action of oral Fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010;33:91-10
25. Takabe K, Paugh SW, Milstien S, et al. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 2008;60:181-95 (Pubitemid 351962008)
26. Dev KK, Mullershausen F, Mattes H, et al. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther 2008;117:77-93 (Pubitemid 350192672)
27. Mehling M, Johnson TA, Antel J, et al. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 2011;76:S20-7
28. Ishii I, Fukushima N, Ye X, et al. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 2004;73:321-54 (Pubitemid 39050372)
29. Kovarik JM, Schmouder R, Barilla D, et al. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol 2004;44:532-7 (Pubitemid 38509722)
30. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355(11):1124-40 (Pubitemid 44394919)
31. O'Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009;72:73-9
32. Comi G, O'Connor P, Montalban X, et al. for the FTY720D2201 Study Group. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 2010;16:197-207
33. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
34. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
35. Leypoldt F, Munchau A, Moeller F, et al. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. Neurology 2009;72:1022-4
36. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Conditions-imposed-on-member-states-for-safe-and-effective-use/human/ 002202/WC500104527.pdf
37. Kasper LH, Due BR, et al. ONO-4641 Study Group. A phase I study to evaluate safety, tolerability and pharmacological properties of a selective sphingosine-1-phosphate (S1P) receptor agonist ONO-4641 in patients with multiple sclerosis poster no. P991. 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis; 13-16 October 2010; Gothenburg
38. Herrmann ML, Schleyerbach R, Kirschbaum BJ. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 2000;47:273-89 (Pubitemid 30394543)
39. Claussen MC, Korn T. Immune mechanisms of new therapeutic strategies in MS-Teriflunomide. Clin Immunol 2011 Feb 28. Epub ahead of print
40. Merrill JE, Hanak S, Pu SF, et al. Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol 2009;256:89-103
41. Bruneau JM, Yea CM, Spinella-Jaegle S, et al. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem J 1998;336:299-303 (Pubitemid 28564384)
42. O'Connor PW, Li D, Freedmann MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006;66:894-900 (Pubitemid 43739766)
43. O'Connor P, Li D, Freedman M, et al. on behalf of the Teriflunomide Multiple Sclerosis Trial Group. Oral teriflunomide is effective and well tolerated in multiple sclerosis with relapses: results of an open-label 144-week extension study Poster 379. Program and abstracts of the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 28 September 2006; Madrid, Spain
44. O'Connor P, Wolinsky J, Confavreux C, et al. A placebo controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis: clinical efficacy and safety outcomes abstract. Mult Scler 2010;16:S23-79
45. Freedman M, Wolinsky JS, Byrnes WJ, et al. Oral teriflunomide or placebo added to interferon beta for 6 months in patients with relapsing multiple sclerosis: safety and efficacy results abstract P878. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 9-12 September 2009; Dusseldorf, Germany. Mult Scler 2009;15(9):S273
46. Freedman M, Wolinsky JS, Frangin GA, et al. Oral teriflunomide or placebo added to glatiramer acetate for 6 months in patients with relapsing multiple sclerosis: Safety and efficacy results abstract S21.001. Presented at: 62nd Annual Meeting of the American Academy of Neurology (AAN); 10-17 April 2010; Toronto, Ont., Canada. Neurology 2010;74(9 SUPPL. 2):A293 Available from: http://clinicaltrials.gov/
47. Brunmark C, Runstrom A, Ohlsson L, et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002;130:163-72 (Pubitemid 35240003)
48. Gurevich M, Gritzman T, Orbach R, et al. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study. J Neuroimmunol 2010;221:87-94
49. Wegner C, Stadelmann C, Pfortner R, et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 2010;227:133-4
50. Polman C, Barkhof F, Sandberg-Wollheim M, et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005;64:987-91 (Pubitemid 40388448)
51. Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008;371:2085-92 (Pubitemid 351842581)
52. Comi G, Abramsky O, Arbizu T, et al. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multicentre, randomized, double-blind, parallel-group placebo controlled study. Mult Scler 2010;16:1360-6
53. Comi G, Jeffrey D, Kappos L, et al. Oral laquinimod reduced relapse rate and delayed progression of disability in ALLEGRO, a placebo-controlled phase III trial for relapsing-remitting multiple sclerosis abstract #P05.288. Presented at: American Academy of Neurology (AAN) 63rd Annual Meeting; 9-16 April 2011
54. Vollmer TL, Soelberg Sorensen P. Arnold DL on behalf of the BRAVO study. A placebo-controlled and active comparator phase III trial (BRAVO) for relapsing-remitting multiple sclerosis. (abstract). Mult Scler 2011;17:S507-24
55. Schweckendiek W. Treatment of psoriasis vulgaris. Med Monatsschr 1959;13:103-4
56. Mrowietz U, Rostami-Yazdi M, Neureither M, et al. 15 years of fumaderm: fumaric acid esters for the systemic treatment of moderately severe and severe psoriasis vulgaris. J Dtsch Dermatol Ges 2009;7(SUPPL. 2):S3-16
57. Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011;134:678-92
58. Vandermeeren M, Janssens S, Borgers M, et al. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun 1997;234:19-23 (Pubitemid 27267523)
59. Treumer F, Zhu K, Glaser R, et al. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003;121:1383-8 (Pubitemid 38005490)
60. Loewe R, Pillinger M, De Martin R, et al. Dimethyl fumarate inhibits tumor-necrosis factor-induced CD62E expression in an NF-kappa B-dependent manner. J Invest Dermatol 2001;117:1363-8
61. Litjens NH, Rademaker M, Ravensbergen B, et al. Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur J Immunol 2004;34:565-75 (Pubitemid 39255966)
62. Schilling S, Goelz S, Linker R, et al. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol 2006;145:101-7 (Pubitemid 43893938)
63. Schimrigk S, Brune N, Hellwig K, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 2006;13:604-10 (Pubitemid 43873632)
64. Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo controlled phase IIb study. Lancet 2008;372:1463-72
65. MacManus DG, Miller DH, Kappos L, et al. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J Neurol 2011;258:449-5
66. Hoefnagel JJ, Thio HB, Willemze R, et al. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003;149:363-9 (Pubitemid 37100263)